BC
AXSM icon

Bayforest Capital’s Axsome Therapeutics AXSM Stock Holding History

Bayforest Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.1K Sell
168
-795
-83% -$172K 0.04% 659
2026
Q1 		$163K Buy
963
+485
+101% +$83.8K 0.18% 188
2025
Q4 		$87.3K Sell
478
-584
-55% -$81.5K 0.07% 500
2025
Q3 		$129K Buy
+1,062
New +$120K 0.06% 473

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bayforest Capital's AXSM Position: Q2 2026 in Review

Bayforest Capital reduced its Axsome Therapeutics (AXSM) stake by 83% in Q2 2026, selling an estimated $172K and leaving 168 shares worth $41.1K. The position accounts for 0.04% of the portfolio, ranked #659.

Bayforest Capital first reported a position in AXSM in Q3 2025 and has held it in 4 quarters since. The position peaked at $163K in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Bayforest Capital held 168 shares of Axsome Therapeutics worth $41.1K as of Q2 2026.
  • Bayforest Capital sold 795 Axsome Therapeutics shares in Q2 2026, an estimated $172K.
  • Axsome Therapeutics made up 0.04% of Bayforest Capital's portfolio in Q2 2026, its #659 holding.
  • Bayforest Capital first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Bayforest Capital's Axsome Therapeutics position peaked at $163K in Q1 2026.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.